Literature DB >> 16028689

Determination of the endogenous nitric oxide synthase inhibitor asymmetric dimethylarginine in biological samples by HPLC.

Tom Teerlink1.   

Abstract

Asymmetric dimethylarginine (ADMA) is an endogenous inhibitor of all isoforms of nitric oxide synthase, the enzyme that synthesizes nitric oxide from arginine. Elevated plasma concentrations of ADMA are associated with hypertension and other risk factors for cardiovascular disease. Symmetric dimethylarginine (SDMA), a stereoisomer of ADMA that does not inhibit nitric oxide synthase, is also present in plasma in concentrations that are almost equal to ADMA concentrations. Any analytical method used for the determination of ADMA should therefore be able to discriminate between ADMA and SDMA. In this chapter a high-performance liquid chromatography (HPLC) method for the simultaneous analysis of arginine, ADMA, and SDMA is described. Solid-phase extraction is used to isolate all basic amino acids. Subsequently, amino acids are converted into relatively stable adducts by derivatization with o-phthalaldehyde reagent containing mercaptopropionic acid. Derivatives are then separated by reversed-phase HPLC using isocratic elution and fluorescence detection. The method requires only 0.05-0.2 mL of sample, allowing the analysis of plasma from small laboratory animals. Because of its high precision, this method is particularly suited to detect small concentration differences between samples, e.g., in the assessment of ADMA metabolism at the organ level by measurement of arterio-venous concentration differences.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 16028689     DOI: 10.1385/1-59259-850-1:263

Source DB:  PubMed          Journal:  Methods Mol Med        ISSN: 1543-1894


  8 in total

1.  Arterial properties in acromegaly: relation to disease activity and associated cardiovascular risk factors.

Authors:  Marianna Yaron; Elena Izkhakov; Jessica Sack; Ibrahim Azzam; Etty Osher; Karen Tordjman; Naftali Stern; Yona Greenman
Journal:  Pituitary       Date:  2016-06       Impact factor: 4.107

2.  Circulating levels of apelin, glucagon-like peptide and visfatin in hypercholesterolemic-hyperhomocysteinemic guinea-pigs: their relation with NO metabolism.

Authors:  Zeynep Kusku-Kiraz; Sema Genc; Seldag Bekpinar; Yesim Unlucerci; Vakur Olgac; Mujdat Uysal; Figen Gurdol
Journal:  Mol Cell Biochem       Date:  2014-11-08       Impact factor: 3.396

3.  Dimethylarginines and inflammation markers in patients with chronic kidney disease undergoing dialysis.

Authors:  Yildiz Oner-Iyidogan; Pernur Oner; Hikmet Kocak; Figen Gurdol; Seldag Bekpinar; Yesim Unlucerci; Yasar Caliskan; Pinar Cetinalp-Demircan; Taner Kocak; Aydin Turkmen
Journal:  Clin Exp Med       Date:  2009-02-24       Impact factor: 3.984

4.  Unchanged asymmetric dimethylarginine levels in non-diabetic, premenopausal obese women who have common risk factors for cardiovascular disease.

Authors:  P Cetinalp-Demircan; A Can; Selda Bekpinar; Y Unlucerci; Y Orhan
Journal:  Endocrine       Date:  2007-04       Impact factor: 3.633

5.  ADMA and SDMA levels in healthy men exposed to tobacco smoke.

Authors:  Andrzej Sobczak; Maciej Lukasz Goniewicz; Izabela Szoltysek-Boldys
Journal:  Atherosclerosis       Date:  2009-01-09       Impact factor: 5.162

6.  Left ventricular diastolic dysfunction and plasma asymmetric dimethylarginine concentration in persons with essential hypertension.

Authors:  Rafał Poręba; Paweł Gać; Małgorzata Poręba; Arkadiusz Derkacz; Angelika Chachaj; Grzegorz Mazur; Andrzej Szuba
Journal:  Arch Med Sci       Date:  2015-06-19       Impact factor: 3.318

7.  L-arginine, asymmetric dimethylarginine, and symmetric dimethylarginine in plasma and synovial fluid of patients with knee osteoarthritis.

Authors:  Valerio Pascale; Walter Pascale; Vito Lavanga; Valerio Sansone; Paolo Ferrario; Vito De Gennaro Colonna
Journal:  Med Sci Monit       Date:  2013-11-26

8.  Assessment of serum arginase I as a type 2 diabetes mellitus diagnosis biomarker in patients.

Authors:  Song Wang; Fang Fang; Wen-Bo Jin; Xia Wang; DA-Wei Zheng
Journal:  Exp Ther Med       Date:  2014-06-06       Impact factor: 2.447

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.